Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Moderna Increases Minimum Supply Of Coronavirus Vaccine Doses For 2021

Company Still Anticipates Up To 1 Billion Doses

Executive Summary

The company’s announcement that it would supply at least 600 million doses of mRNA-1273 came as US vaccination rates have fallen far short of expectations.

You may also be interested in...



Speculation Over Moderna Vaccine Deal With Tata, Wockhardt

Moderna is speculated to be in talks with Indian firms, including Wockhardt and a Tata group company, for manufacturing and/or marketing its COVID-19 vaccine. A deal in India could help the company meet its obligation to supply COVAX but Moderna is likely to choose its partner carefully.

A Commercial-Stage Moderna Debuts At J.P. Morgan

Moderna has received $2.8bn for advance purchase agreements for its COVID-19 vaccine, with much more to follow. Management outlined some initial financial updates for investors.

Moderna Implements More Expansive Employee COVID-19 Vaccination Program Than Pfizer

Moderna will give its coronavirus vaccine to employees immediately, while Pfizer will wait until workers are eligible under prioritization guidelines.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143566

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel